Regulation of secondary lymphoid organ development by the nuclear factor-κB signal transduction pathway

Immunological Reviews

Volumn 195, Issue , 2003, Pages 91-105

  Weih, Falk ^a   Caamaño, Jorge ^b  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOTRANSFERASE; TUMOR NECROSIS FACTOR RECEPTOR;

ACCESSORY CELL; B LYMPHOCYTE; BONE MARROW; CELL DIFFERENTIATION; CELL MATURATION; CELL STRUCTURE; ENZYME ACTIVATION; HISTOPATHOLOGY; LYMPH NODE; LYMPHOID ORGAN; NONHUMAN; ORGANOGENESIS; PEYER PATCH; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPLEEN; STEM CELL; T LYMPHOCYTE; THYMUS;

ANIMALS; HUMANS; LYMPH NODES; NF-KAPPA B; PEYER'S PATCHES; SIGNAL TRANSDUCTION; SPLEEN;

EID: 0141567432     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00064.x     Document Type: Review

References (112)

1. Castenholz A. Architecture of the lymph node with regard to its function. Curr Top Pathol 1990;84:1-32.
2. Timens W. The human spleen and the immune system: not just another lymphoid organ. Res Immunol 1991;142:316-320.
3. Witmer MD, Steinman RM. The anatomy of peripheral lymphoid organs with emphasis on accessory cells: light-microscopic immunocytochemical studies of mouse spleen, lymph node, and Peyer's patch. Am J Anat 1984;170:465-481.
4. Tew JG, Wu J, Qin D, Helm S, Burton GF, Szakal AK. Follicular dendritic cells and presentation of antigen and costimulatory signals to B cells. Immunol Rev 1997;156:39-52.
5. Steinman RM, Pack M, Inaba K. Dendritic cells in the T-cell areas of lymphoid organs. Immunol Rev 1997;156:25-37.
6. Fu Y-X, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 1999;17:399-433.
7. Matsumoto M. Role of TNF ligand and receptor family in the lymphoid organogenesis defined by gene targeting. J Med Invest 1999;46:141-150.
8. Grossmann M, Nakamura Y, Grumont R, Gerondakis S. New insights into the roles of Rel/NF-κB transcription factors in immune function, hemopoiesis and human disease. Int J Biochem Cell Biol 1999;31:1209-1219.
9. Silverman N, Maniatis T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev 2001;15:2321-2342.
10. Caamaño J, Hunter CA. NF-κB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev 2002;15:414-429.
11. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002;3:221-227.
12. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;1:301-310.
13. Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol 2002;2:725-734.
14. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999;18:6853-6866.
15. Karin M & Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000;18:621-663.
16. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109 (Suppl): S81-S96.
17. Pomerantz JL & Baltimore D. Two pathways to NF-κB. Mol Cell 2002;10:693-695.
18. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-mduced NEMO-independent processing of NF-κB2 in maturing B cells. Nat Immunol 2002;3:958-965.
19. Coope HJ, et al. CD40 regulates the processing of NF-κB2 p100 to p52. EMBO J 2002;21:5375-5385.
20. Dejardin E, et al. The lymphotoxin-β receptor induces different patterns of gene expression via two NF-κB pathways. Immunity 2002;17:525-535.
21. Kayagaki N, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity 2002;17:515-524.
22. Mordmüller B, Krappmann D, Esen M, Wegener E, Scheidereit C. Lymphotoxin and lipopolysaccharide induce NF-κB-p52 generation by a co-translational mechanism. EMBO Rep 2003;4:82-87.
23. Müller JR, Siebenlist U. Lymphotoxin β receptor induces sequential activation of distinct NF-κB factors via separate signaling pathways. J Biol Chem 2003;28:12006-12012.
24. Yilmaz ZB, Weih DS, Sivakumar V, Weih F. RelB is required for Peyer's patch development: differential regulation of p52-RelB heterodimers by lymphotoxin and TNF. EMBO J 2003;22:121-130.
25. Ryseck R-P, Weih F, Carrasco D, Bravo R. RelB, a member of the Rel/NF-κB family of transcription factors. Braz J Med Biol Res 1996;29:895-903.
26. Dobrzanski P, Ryseck R-P, Bravo R. Differential interaction of Rel/NF-κB complexes with IκBα determine pools of constitutive and inducible NF-κB activity. EMBO J 1994;13:4608-4616.
27. Lernbecher T, Kistler B, Wirth T. Two distinct mechanisms contribute to the constitutive activation of RelB in lymphoid cells. EMBO J 1994;13:4060-4069.
28. Weih F, Carrasco D, Bravo R. Constitutive and inducible Rel/NF-κB activities in mouse thymus and spleen. Oncogene 1994;9:3289-3297.
29. Attar RM, et al. Genetic approaches to study Rel/NF-κB/IκB function in mice. Semin Cancer Biol 1997;8:93-101.
30. Gerondakis S, Grossmann M, Nakamura Y, Pohl T, Grumont R. Genetic approaches in mice to understand Rel/NF-κB and IκB function: transgenics and knockouts. Oncogene 1999;18:6888-6895.
31. Kosco-Vilbois MH, Bonnefoy JY, Chvatchko Y. The physiology of murine germinal center reactions. Immunol Rev 1997;156:127-136.
32. Kosco-Vilbois MH & Scheidegger D. Follicular dendritic cells: antigen retention, B cell activation, and cytokine production. Curr Top Microbiol Immunol 1995;201:69-82.
33. Sha WC, Liou H-C, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 1995;80:321-330.
34. Weih F, et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 1995;80:331-340.
35. Caamaño, JH, et al. Nuclear factor (NF) -κB2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med 1998;187:185-196.
36. Franzoso G, et al. Mice deficient in nuclear factor (NF)-κB/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 1998;187:147-159.
37. Poljak L, Carlson L, Cunningham K, Kosco-Vilbois MH, Siebenlist U. Distinct activities of p52/NF-κB required for proper secondary lymphoid organ microarchitecture: functions enhanced by Bcl-3. J Immunol 1999;163:6581-6588.
38. Weih DS, Yilmaz ZB, Weih F. Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines. J Immunol 2001;167:1909-1919.
39. Köntgen F, et al. Mice lacking the c-rel protooncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 1995;9:1965-1977.
40. Carrasco D, et al. Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein. J Exp Med 1998;187:973-984.
41. Liou H-C, Jin Z, Tumang J, Andjelic S, Smith KA, Liou M-L. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int Immunol 1999;11:361-371.
42. Tumang JR, et al. c-Rel is essential for B lymphocyte survival and cell cycle progression. Eur J Immunol 1998;28:4299-4312.
43. Chen LL, Frank AM, Adams JC, Steinman RM. Distribution of horseradish peroxidase (HRP)-anti-HRP immune complexes in mouse spleen with special reference to follicular dendritic cells. J Cell Biol 1978;79:184-199.
44. Fujita T, Nolan GP, Liou H-C, Scott ML, Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers. Genes Dev 1993;7:1354-1363.
45. Bours V, et al. The oncoprotein Bcl-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers. Cell 1993;72:729-739.
46. Franzoso G, et al. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture and germinal center reactions. Immunity 1997;6:479-490.
47. Schwarz EM, Krimpenfort P, Berns A, Verma IM. Immunological defects in mice with a targeted disruption in Bcl-3. Genes Dev 1997;11:187-197.
48. Kraal G. Cells in the marginal zone of the spleen. Int Rev Cytol 1992;132:31-74.
49. Cyster JG. B cells on the front line. Nat Immunol 2000;1:9-10.
50. van Vliet E, Melis M, van Ewijk W. Marginal zone macrophages in the mouse spleen identified by a monoclonal antibody: anatomical correlation with a B cell subpopulation. J Histochem Cytochem 1985;33:40-44.
51. Kraal G, Janse M. Marginal metallophilic cells of the mouse spleen identified by a moonoclonal antibody. Immunology 1986;58:665-669.
52. Kraal G, Schornagd K, Streeter PR, Holzmann B, Butcher EC. Expression of the mucosal vascular addressin, MAdCAM-1, on sinus-lining cells in the spleen. Am J Pathol 1995;147:763-771.
53. Szabo MC, Butcher EC, McEvoy LM. Specialization of mucosal follicular dendritic cells revealed by mucosal addressin-cell adhesion molecule-1 display. J Immunol 1997;158:5584-5588.
54. van Vliet E, Melis M, Foidart JM, Van Ewijk W. Reticular fibroblasts in peripheral lymphoid organs identified by a monodonal antibody. J Histochem Cytochem 1986;34:883-890.
55. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol 2002;2:323-335.
56. Cariappa A, Liou H-C, Horwitz BH, Pillai S. Nuclear factor κB is required for the development of marginal zone B lymphocytes. J Exp Med 2000;192:1175-1182.
57. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 1995;376:167-169.
58. Alcamo E, Hacohen N, Schulte LC, Rennert PD, Hynes RO, Baltimore D. Requirement for the NF-κB family member RelA in the devdopment of secondary lymphoid organs. J Exp Med 2002;195:233-244.
59. Pasparakis M, Kousteni S, Peschon J, Kollias G. Tumor necrosis factor and the p55TNF receptor are required for optimal devdopment of the marginal sinus and for migration of follicular dendritic cell precursors into splenic follides. Cell Immunol 2000;201:33-41.
60. Li Q, van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science 1999;284:321-325.
61. Tanaka M, et al. Embryonic lethality, liver degeneration, and impaired NF-κB activation in IKK-β-deficient mice. Immunity 1999;10:421-429.
62. Rudolph D, et al. Severe liver degeneration and lack of NF-κB activation in NEMO/IKKγ-deficient mice. Genes Dev 2000;14:854-862.
63. Schmidt-Supprian M, et al. NEMO/IKKγ-deficient mice model incontinentia pigmenti. Mol Cell 2000;5:981-992.
64. Hu Y, et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science 1999;284:316-320.
65. Takeda K, et al. Limb and skin abnormalities in mice lacking IKKα. Science 1999;284:313-316.
66. Senftleben U, et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 2001;293:1495-1499.
67. Gerondakis S, Grumont R, Rourke I, Grossmann M. The regulation and roles of Rel/NF-κB transcription factors during lymphocyte activation. Curr Opin Immunol 1998;10:353-359.
68. Gugasyan R, et al. Rel/NF-κB transcription factors: key mediators of B-cell activation. Immunol Rev 2000;176:134-140.
69. Horwitz BH, Scott ML, Cherry SR, Bronson RT, Baltimore D. Failure of lymphopoiesis after adoptive transfer of NF-κB-deficient liver cells. Immunity 1997;6:765-772.
70. Kaisho T, et al. IκB kinase α is essential for mature B cell development and function. J Exp Med 2001;193:417-426.
71. Pasparakis M, Schmidt-Supprian M, Rajewsky K. IκB kinase signaling is essential for maintenance of mature B cells. J Exp Med 2002;196:743-752.
72. Senftleben U, Li ZW, Baud V, Karin M. IKKβ is essential for protecting T cells from TNFα-induced apoptosis. Immunity 2001;14:217-230.
73. Sen R, Baltimore D. Inducibility of immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism. Cell 1986;47:921-928.
74. Miyawaki S, et al. A new mutation, aly, that induces a generalised lack of lymph nodes accompanied by immunodeficiency in mice. Eur J Immunol 1994;24:429-434.
75. Koike R, et al. The splenic marginal zone is absent in alymphoplastic aly mutant mice. Eur J Immunol 1996;26:669-675.
76. Shinkura R, et al. Defects of somatic hypermutation and class switching in alymphoplasia (aly) mutant mice. Int Immunol 1996;8:1067-1075.
77. -/-) mutant mice. J Exp Med 1997;185:2157-2170.
78. Shinkura R, et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-κb-inducing kinase. Nat Genet 1999;22:74-77.
79. + cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity 1997;7:493-504.
80. - cells in the embryonic intestine induce the organizing center of Peyer's patches. Int Immunol 1999;11:643-655.
81. - cells in lymphoid organ development. Immunol Rev 2002;189:41-50.
82. Hashi H, et al. Compartmentalization of Peyer's patch anlagen before lymphocyte entry. J Immunol 2001;166:3702-3709.
83. Ngo VN, et al. Lymphotoxin α/β and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med 1999;189:403-412.
84. Yoshida H, et al. Different cytokines induce surface lymphotoxin-α β on IL-7 receptor-α cells that differentially engender lymph nodes and Peyer's patches. Immunity 2002;17:823-833.
85. Ansel KM, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000;406:309-314.
86. - cells to colonize lymph nodes. Proc Natl Acad Sci USA 1996;93:11019-11024.
87. Ansel KM, Cyster JG. Chemokines in lymphopoiesis and lymphoid organ development. Curr Opin Immunol 2001;13:172-179.
88. Rennert PD, James D, Mackay F, Browning JL, Hochman PS. Lymph node genesis is induced by signaling through the lymphotoxin β receptor. Immunity 1998;9:71-79.
89. Kuprash DV, Alimzhanov MB, Tumanov AV, Anderson AO, Pfeffer K, Nedospasov SA. TNF and lymphotoxin β cooperate in the maintenance of secondary lymphoid tissue microarchitecture but not in the development of lymph nodes. J Immunol 1999;163:6575-6580.
90. Kim D, et al. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med 2000;192:1467-1478.
91. Dougall WC, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-2424.
92. Kong TY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
93. Lomaga MA, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999;13:1015-1024.
94. Naito A, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999;4:353-362.
95. Xiao G, Harhaj EW, Sun S-C. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell 2001;7:401-409.
96. Yamada T, et al. Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-κB-inducing kinase. J Immunol 2000;165:804-812.
97. Debard N, Sierro F, Kraehenbuhl JP. Development of Peyer's patches, follicle-associated epithelium and M cell: lessons from immunodeficient and knockout mice. Semin Immunol 1999;11:183-191.
98. Griebel PJ, Hein WR. Expanding the role of Peyer's patches in B-cell ontogeny. Immunol Today 1996;17:30-39.
99. Adachi S, Yoshida H, Kataoka H, Nishikawa S. Three distinctive steps in Peyer's patch formation of murine embryo. Int Immunol 1997;9:507-514.
100. Nishikawa S, Honda K, Hashi H, Yoshida H. Peyer's patch organogenesis as a programmed inflammation: a hypothetical model. Cytokine Growth Factor Rev 1998;9:213-220.
101. Pasparakis M, Alexopoulou L, Grell M, Pfizenmaier K, Bluethmann H, Kollias G. Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. Proc Natl Acad Sci USA 1997;94:6319-6323.
102. Paxian S, et al. Abnormal organogenesis of Peyer's patches in mice deficient for NF-κB1, NF-κB2, and Bcl-3. Gastroenterology 2002;122:1853-1868.
103. Matsushima A, et al. Essential role of nuclear factor (NF)-κB-inducing kinase and inhibitor of κB (IκB) kinase α in NF-κB activation through lymphotoxin β receptor, but not through tumor necrosis factor receptor I. J Exp Med 2001;191:631-636.
104. Kuper CF, Hameleers DM, Bruijntjes JP, van der Ven I, Biewenga J, Sminia T. Lymphoid and non-lymphoid cells in nasal-associated lymphoid tissue (NALT) in the rat: an immuno- and enzyme-histochemical study. Cell Tissue Res 1990;259:371-377.
105. van der Ven I, Sminia T. The development and structure of mouse nasal-associated lymphoid tissue: an immuno- and enzyme-histochemical study. Reg Immunol 1993;5:69-75.
106. Jeong KI, Suzuki H, Nakayama H, Doi K. Ultrastructural study on the follicle-associated epithelium of nasal-associated lymphoid tissue in specific pathogen-free (SPF) and conventional environment-adapted (SPF-CV) rats. J Anat 2000;196:443-451.
107. Shimoda M, et al. Isotype-specific selection of high affinity memory B cells in nasal-associated lymphoid tissue. J Exp Med 2001;194:1597-1607.
108. 5+ cells. Immunity 2002;17:31-40.
109. Harmsen A, et al. Organogenesis of nasal-associated lymphoid tissue (NALT) occurs independently of lymphotoxin-α (LTα) and retinoic acid receptor-related orphan receptor-γ, but the organization of NALT is LTα dependent. J Immunol 2002;168:986-990.
110. - cells induce Peyer's patch development: role of α4β1 integrin activation by CXCRS. Immunity 2002;17:363-373.
111. Franzoso G, et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev 1997;11:3482-3496.
112. Iotsova V, Caamaño J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 1997;3:1285-1289.